Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924088 | 1.00 | HIF1A (0.41) | HIF1AHDAC4OPRL1GAAMEN1 | |
| SCHEMBL6457746 | 1.00 | HIF1A (0.41) | HIF1AHDAC4OPRL1GAAMEN1 | |
| SCHEMBL6459488 | 0.80 | SLC6A4 (0.46) | GAAALDH1A1 | |
| SCHEMBL6456277 | 0.80 | SLC6A4 (0.46) | GAAALDH1A1 | |
| SCHEMBL517632 | 0.78 | ALOX5 (0.41) | KMT2AALDH1A1OPRK1 | |
| SCHEMBL5526742 | 0.77 | HDAC4 (0.41) | HIF1AHDAC4GAACES2CES1 | |
| SCHEMBL6457653 | 0.76 | HSD11B1 (0.39) | ALDH1A1 | |
| SCHEMBL6922904 | 0.76 | HSD11B1 (0.39) | ALDH1A1 | |
| SCHEMBL6462324 | 0.76 | HSD11B1 (0.39) | ALDH1A1 | |
| SCHEMBL624819 | 0.73 | GRM4 (0.41) | HIF1AHDAC4KMT2ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | HIF1A 1487/4885HDAC4 2734/4885OPRL1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.